Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Hodmezovasarhely – page 2

29 clinical trials in Hodmezovasarhely, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Hodmezovasarhely at a glance
29
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

29 trials in Hodmezovasarhely

Open in trial search

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A Study Testing Imeroprubart for Adults with Primary Sjogren's Disease with Moderate to Severe Symptoms

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Rheumatoid arthritis

Not recruiting

Study on the Effects of IMVT-1402 for Adults with Difficult-to-Treat Rheumatoid Arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study of sonelokimab and risankizumab in adults with psoriatic arthritis who did not respond well to previous TNF inhibitor treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:MoonLake Immunotherapeutics AG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study on the Effectiveness and Safety of Abatacept Biosimilar (DRL_AB) and Methotrexate for Patients with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Dr Reddy's Laboratories Limited

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Axial spondyloarthritis

Not recruiting

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Hodmezovasarhely

What the registry says about research in the country

01 Rheumatologic Conditions

Clinical research focusing on innovative treatments for rheumatoid arthritis and psoriatic arthritis, including evaluation of novel biologics and combination therapies.

  • Rheumatoid Arthritis Studies
  • Psoriatic Arthritis Treatments
  • Sjögren's Syndrome Research

Multiple trials are examining both bio-naive patients and those with inadequate response to previous treatments.

02 Cardiovascular Research

Groundbreaking studies addressing cardiovascular diseases and related conditions, with focus on preventing major adverse cardiovascular events.

  • Atherosclerotic Disease Management
  • Heart Failure Treatments
  • Atrial Fibrillation Studies

Research includes innovative approaches to lipid management and heart failure complications.

03 Autoimmune Disorders

Comprehensive research into autoimmune conditions, evaluating new therapeutic options and treatment approaches.

  • Plaque Psoriasis Studies
  • Axial Spondyloarthritis Research
  • Systemic Disease Management

Trials focus on both established and experimental treatments for various autoimmune manifestations.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.